| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VARS2 |
| Uniprot No | P26640 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1264aa |
| 氨基酸序列 | MSTLYVSPHPDAFPSLRALIAARYGEAGEGPGWGGAHPRICLQPPPTSRTPFPPPRLPALEQGPGGLWVWGATAVAQLLWPAGLGGPGGSRAAVLVQQWVSYADTELIPAACGATLPALGLRSSAQDPQAVLGALGRALSPLEEWLRLHTYLAGEAPTLADLAAVTALLLPFRYVLDPPARRIWNNVTRWFVTCVRQPEFRAVLGEVVLYSGARPLSHQPGPEAPALPKTAAQLKKEAKKREKLEKFQQKQKIQQQQPPPGEKKPKPEKREKRDPGVITYDLPTPPGEKKDVSGPMPDSYSPRYVEAAWYPWWEQQGFFKPEYGRPNVSAANPRGVFMMCIPPPNVTGSLHLGHALTNAIQDSLTRWHRMRGETTLWNPGCDHAGIATQVVVEKKLWREQGLSRHQLGREAFLQEVWKWKEEKGDRIYHQLKKLGSSLDWDRACFTMDPKLSAAVTEAFVRLHEEGIIYRSTRLVNWSCTLNSAISDIEVDKKELTGRTLLSVPGYKEKVEFGVLVSFAYKVQGSDSDEEVVVATTRIETMLGDVAVAVHPKDTRYQHLKGKNVIHPFLSRSLPIVFDEFVDMDFGTGAVKITPAHDQNDYEVGQRHGLEAISIMDSRGALINVPPPFLGLPRFEARKAVLVALKERGLFRGIEDNPMVVPLCNRSKDVVEPLLRPQWYVRCGEMAQAASAAVTRGDLRILPEAHQRTWHAWMDNIREWCISRQLWWGHRIPAYFVTVSDPAVPPGEDPDGRYWVSGRNEAEAREKAAKEFGVSPDKISLQQDEDVLDTWFSSGLFPLSILGWPNQSEDLSVFYPGTLLETGHDILFFWVARMVMLGLKLTGRLPFREVYLHAIVRDAHGRKMSKSLGNVIDPLDVIYGISLQGLHNQLLNSNLDPSEVEKAKEGQKADFPAGIPECGTDALRFGLCAYMSQGRDINLDVNRILGYRHFCNKLWNATKFALRGLGKGFVPSPTSQPGGHESLVDRWIRSRLTEAVRLSNQGFQAYDFPAVTTAQYSFWLYELCDVYLECLKPVLNGVDQVAAECARQTLYTCLDVGLRLLSPFMPFVTEELFQRLPRRMPQAPPSLCVTPYPEPSECSWKDPEAEAALELALSITRAVRSLRADYNLTRIRPDCFLEVADEATGALASAVSGYVQALASAGVVAVLALGAPAPQGCAVALASDRCSIHLQLQGLVDPARELGKLQAKRVEAQRQAQRLRERRAASGYPVKVPLEVQEADEAKLQQTEAELRKVDEAIALFQKML |
| 预测分子量 | 140 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VARS2重组蛋白的3篇代表性文献及其摘要内容概括：
1. **文献名称**：*"Biochemical analysis of human VARS2 variants reveals divergent impacts on mitochondrial translation"*
**作者**：Diodato D, et al.
**摘要**：该研究通过在大肠杆菌中表达并纯化重组人源VARS2蛋白，分析其氨基酸酰化酶活性，揭示了不同致病突变对线粒体蛋白质翻译效率的影响，为相关线粒体脑肌病的机制提供分子基础。
2. **文献名称**：*"Structural insights into the pathogenicity of VARS2 mutations in mitochondrial disorders"*
**作者**：Nakamura H, et al.
**摘要**：通过X射线晶体学解析重组VARS2蛋白的结构，发现其催化结构域中特定突变会导致tRNA结合能力下降，阐明了突变引起酶功能缺陷的结构生物学机制。
3. **文献名称**：*"A Drosophila model of VARS2-related mitochondrial disease reveals neuromuscular dysfunction"*
**作者**：Zhang X, et al.
**摘要**：利用重组VARS2蛋白在果蝇模型中验证其保守功能，发现蛋白表达缺陷会导致线粒体呼吸链复合体组装异常，进而引发运动神经元退化表型。
(注：以上文献信息为基于领域知识的模拟概括，实际文献需通过PubMed或专业数据库检索确认。)
VARS2 (Valyl-tRNA Synthetase 2) is a mitochondrial aminoacyl-tRNA synthetase (mt-ARS) essential for protein synthesis within mitochondria. It catalyzes the attachment of valine to its cognate mitochondrial tRNA (tRNAᵛᵃˡ), a critical step in mitochondrial translation. This process supports the production of respiratory chain complexes involved in oxidative phosphorylation (OXPHOS), the primary energy-generating pathway in eukaryotic cells. As a nuclear-encoded protein, VARS2 is synthesized in the cytoplasm and transported into mitochondria, where its function is tightly linked to mitochondrial genome integrity and metabolic homeostasis.
Mutations in the *VARS2* gene are associated with mitochondrial disorders, often presenting as severe neurodevelopmental or neurodegenerative conditions. Clinical phenotypes include encephalopathy, hypertrophic cardiomyopathy, epilepsy, and Leigh-like syndrome, reflecting the high energy demands of the brain and heart. Pathogenic variants disrupt valine tRNA charging, impairing mitochondrial protein synthesis and leading to OXPHOS deficiency. These discoveries have emerged from genomic studies of affected patients and functional validation in cellular or animal models.
Recombinant VARS2 protein is engineered for *in vitro* studies to dissect its enzymatic mechanisms, substrate interactions, and structural dynamics. Its production typically involves heterologous expression systems (e.g., *E. coli* or mammalian cells) followed by purification. Researchers use recombinant VARS2 to investigate disease-causing mutations, screen potential therapeutic compounds, or analyze post-translational modifications influencing its activity. Recent structural studies leveraging recombinant protein have revealed insights into tRNA-binding domains and mutation hotspots. Additionally, recombinant VARS2 serves as a tool to explore broader questions about mitochondrial translation fidelity and its role in cellular stress responses. Ongoing work aims to link VARS2 dysfunction to metabolic reprogramming in cancer and aging, expanding its relevance beyond rare genetic diseases.
×
